{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:36Z","timestamp":1793286216862,"version":"4.5.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The development of immune checkpoint inhibitors (ICIs) represents a paradigm shift in the treatment of cancers. Despite showing remarkable efficacy, these agents can be associated with life-threatening immune-related adverse events. In recent years, several cases of myocarditis with myositis and\/or myasthenia gravis overlap syndrome (IM3OS) have been reported. However, given the rarity, the clinical features and outcomes of these cases remain poorly understood. We, therefore, attempted to systematically review and summarize all cases of IM3OS reported in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Studies reporting IM3OS were identified in Embase and MEDLINE. Only case reports and case series published in journals or presented at conferences were included. We conducted a systematic review according to the PRISMA Harms guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 60 cases were eligible. The patients\u2019 median age was 71\u2009years, and the majority (67%) were males; melanoma was the most common indication for ICIs (38%). The most-reported symptoms were fatigue (80%) and muscle weakness (78%). The median number of doses to the development of IM3OS was one. The average creatine kinase level was 9,645 IU\/L. Cardiac arrhythmias occurred in 67% of patients, and 18% had depressed ejection fraction. Initial treatment consisted of immunosuppression with high-dose steroids and supportive therapies. Sixty percent of the patients died in hospital because of acute complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IM3OS can be associated with significant mortality and morbidity. Prospective studies are needed to understand the optimal approach to diagnose and manage these patients and to develop biomarkers to predict the occurrence and severity of this rare but serious condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Clinicians should suspect coexisting myositis and\/or myasthenia gravis in all patients with immune checkpoint inhibitor-induced myocarditis, given their propensity to occur together. Early recognition and prompt treatment with the help of a multidisciplinary team might help improve the outcomes of this life-threatening condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13931","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T23:21:32Z","timestamp":1628637692000},"page":"1052-1061","source":"Crossref","is-referenced-by-count":215,"title":["Immune Checkpoint Inhibitor\u2013Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases"],"prefix":"10.1093","volume":"26","author":[{"given":"Ranjan","family":"Pathak","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-242X","authenticated-orcid":false,"given":"Anjan","family":"Katel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M","family":"Villaflor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-4235","authenticated-orcid":false,"given":"Virginia","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Population Science, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"2022011918065949000_onco13931-bib-0001","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022011918065949000_onco13931-bib-0002","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2022011918065949000_onco13931-bib-0003","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: Improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"2022011918065949000_onco13931-bib-0004","first-page":"21","article-title":"Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: An institutional case series","volume":"6","author":"Arora","year":"2020","journal-title":"Cardiooncology"},{"key":"2022011918065949000_onco13931-bib-0005","first-page":"44","article-title":"Pembrolizumab-induced myositis in the setting of metastatic melanoma: An increasingly common phenomenon","volume":"13","author":"Swali","year":"2020","journal-title":"J Clin Aesthetic Dermatol"},{"key":"2022011918065949000_onco13931-bib-0006","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"2022011918065949000_onco13931-bib-0007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2018.10.025","article-title":"Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody","volume":"106","author":"Shirai","year":"2019","journal-title":"Eur J Cancer"},{"key":"2022011918065949000_onco13931-bib-0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ensci.2018.11.023","article-title":"Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life-threatening continuum of neuromuscular and cardiac toxicity","volume":"14","author":"Rota","year":"2019","journal-title":"eNeurologicalSci"},{"key":"2022011918065949000_onco13931-bib-0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-019-0811-3","article-title":"Immune checkpoint inhibitor-induced myositis: A case report and literature review","volume":"21","author":"Kadota","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2022011918065949000_onco13931-bib-0010","article-title":"The terrible triad of checkpoint inhibition: A case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Rep Immunol"},{"key":"2022011918065949000_onco13931-bib-0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2019.02.023","article-title":"PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis","volume":"399","author":"So","year":"2019","journal-title":"J Neurol Sci"},{"issue":"20","key":"2022011918065949000_onco13931-bib-0012","first-page":"30098","article-title":"Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma","volume":"S1658-3876","author":"Fuentes-Antr\u00e1s","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2022011918065949000_onco13931-bib-0013","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis concomitant with myasthenia gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol"},{"key":"2022011918065949000_onco13931-bib-0014","doi-asserted-by":"crossref","first-page":"682262","DOI":"10.3389\/fimmu.2021.682262","article-title":"Immune myocarditis overlapping with myasthenia gravis due to anti-PD-1 treatment for a chordoma patient: A case report and literature review","volume":"12","author":"Liang","year":"2021","journal-title":"Front Immunol"},{"key":"2022011918065949000_onco13931-bib-0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2022011918065949000_onco13931-bib-0016","doi-asserted-by":"crossref","first-page":"101508","DOI":"10.1016\/j.eucr.2020.101508","article-title":"Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management","volume":"34","author":"Yanase","year":"2021","journal-title":"Urol Case Rep"},{"key":"2022011918065949000_onco13931-bib-0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"key":"2022011918065949000_onco13931-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa051","article-title":"Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: A case report","volume":"4","author":"Szuchan","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"2022011918065949000_onco13931-bib-0019","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/CAD.0000000000000903","article-title":"Myositis and myasthenia during nivolumab administration for advanced lung cancer: A case report and review of the literature","volume":"31","author":"Veccia","year":"2020","journal-title":"Anticancer Drugs"},{"key":"2022011918065949000_onco13931-bib-0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nmd.2019.10.006","article-title":"Nivolumab and ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","author":"Valenti-Azcarate","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2022011918065949000_onco13931-bib-0021","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2022011918065949000_onco13931-bib-0022","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-236357","article-title":"Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma","volume":"13","author":"Sessums","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2022011918065949000_onco13931-bib-0023","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.11.026","article-title":"Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab","volume":"91","author":"Nasr","year":"2018","journal-title":"Eur J Cancer"},{"key":"2022011918065949000_onco13931-bib-0024","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1536\/ihj.20-162","article-title":"A fatal case of myocarditis following myositis induced by pembrolizumab treatment for metastatic upper urinary tract urothelial carcinoma","volume":"61","author":"Matsui","year":"2020","journal-title":"Int Heart J."},{"key":"2022011918065949000_onco13931-bib-0025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/01676830.2018.1490439","article-title":"Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia","volume":"38","author":"Hellman","year":"2019","journal-title":"Orbit"},{"key":"2022011918065949000_onco13931-bib-0026","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"2022011918065949000_onco13931-bib-0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/iju5.12128","article-title":"Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Todo","year":"2020","journal-title":"IJU Case Rep."},{"key":"2022011918065949000_onco13931-bib-0028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2022011918065949000_onco13931-bib-0029","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40425-018-0473-0","article-title":"Myocarditis in a patient treated with Nivolumab and PROSTVAC: A case report","volume":"6","author":"Monge","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2022011918065949000_onco13931-bib-0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.21037\/tlcr.2020.02.05","article-title":"Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: Case report","volume":"9","author":"Lie","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2022011918065949000_onco13931-bib-0031","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CJI.0000000000000356","article-title":"Cardiac troponin I and T in checkpoint inhibitor\u2013associated myositis and myocarditis","volume":"44","author":"Ang","year":"2021","journal-title":"J Immunother"},{"key":"2022011918065949000_onco13931-bib-0032","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/L17-0396","article-title":"Survival after fulminant myocarditis induced by immune-checkpoint inhibitors","volume":"167","author":"Arangalage","year":"2017","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"2022011918065949000_onco13931-bib-0033","first-page":"16a","article-title":"Acute myocarditis and myositis after immune checkpoint inhibition","volume":"19","author":"Witham","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022011918065949000_onco13931-bib-0034","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2020.03.003","article-title":"Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade","volume":"132","author":"Tomoaia","year":"2020","journal-title":"Eur J Cancer"},{"key":"2022011918065949000_onco13931-bib-0035","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.3747\/co.26.4381","article-title":"Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab","volume":"26","author":"Saibil","year":"2019","journal-title":"Curr Oncol"},{"key":"2022011918065949000_onco13931-bib-0036","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.3324\/haematol.2017.185777","article-title":"Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity","volume":"103","author":"Martinez-Calle","year":"2018","journal-title":"Haematologica"},{"key":"2022011918065949000_onco13931-bib-0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-019-0132-2","article-title":"Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation","volume":"8","author":"Charles","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"2022011918065949000_onco13931-bib-0038","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"2022011918065949000_onco13931-bib-0039","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2022011918065949000_onco13931-bib-0040","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.jtho.2018.10.156","article-title":"Fulminant myocarditis caused by an immune checkpoint inhibitor: A case report with pathologic findings","volume":"14","author":"Imai","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2022011918065949000_onco13931-bib-0041","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0046-8177(87)80363-5","article-title":"Myocarditis: The Dallas criteria","volume":"18","author":"Aretz","year":"1987","journal-title":"Hum Pathol"},{"key":"2022011918065949000_onco13931-bib-0042","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"2022011918065949000_onco13931-bib-0043","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022011918065949000_onco13931-bib-0044","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022011918065949000_onco13931-bib-0045","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2022011918065949000_onco13931-bib-0046","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"2022011918065949000_onco13931-bib-0047","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2019.07.025","article-title":"Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review","volume":"296","author":"Pradhan","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022011918065949000_onco13931-bib-0048","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIRCULATIONAHA.105.589663","article-title":"Diagnosis of myocarditis: Death of Dallas criteria","volume":"113","author":"Baughman","year":"2006","journal-title":"Circulation"},{"key":"2022011918065949000_onco13931-bib-0049","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"2022011918065949000_onco13931-bib-0050","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022011918065949000_onco13931-bib-0051","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis, and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"2022011918065949000_onco13931-bib-0052","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: Emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"2022011918065949000_onco13931-bib-0053","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"2022011918065949000_onco13931-bib-0054","first-page":"548","article-title":"Isolated elevation of aldolase in the serum of myositis patients: A potential biomarker of damaged early regenerating muscle cells","volume":"30","author":"Casciola-Rosen","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2022011918065949000_onco13931-bib-0055","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"key":"2022011918065949000_onco13931-bib-0056","doi-asserted-by":"crossref","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022011918065949000_onco13931-bib-0057","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"New Engl J Med"},{"key":"2022011918065949000_onco13931-bib-0058","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"New Engl J Med"},{"key":"2022011918065949000_onco13931-bib-0059","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: Pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2022011918065949000_onco13931-bib-0060","doi-asserted-by":"crossref","first-page":"107211","DOI":"10.1016\/j.carpath.2020.107211","article-title":"Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy","volume":"47","author":"Balanescu","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"2022011918065949000_onco13931-bib-0061","doi-asserted-by":"crossref","first-page":"812.e1","DOI":"10.1016\/j.cjca.2018.03.007","article-title":"Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab","volume":"34","author":"Yamaguchi","year":"2018","journal-title":"Can J Cardiol"},{"key":"2022011918065949000_onco13931-bib-0062","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","article-title":"Plasma exchange for immune checkpoint inhibitor\u2013induced myocarditis","volume":"3","author":"Yogasundaram","year":"2021","journal-title":"CJC Open"},{"key":"2022011918065949000_onco13931-bib-0063","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"2022011918065949000_onco13931-bib-0064","doi-asserted-by":"crossref","first-page":"13497","DOI":"10.1038\/s41598-020-70539-4","article-title":"Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis","volume":"10","author":"D\u00edez-Porras","year":"2020","journal-title":"Sci Rep"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13931","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/12\/1052\/42242568\/oncolo_26_12_1052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/12\/1052\/42242568\/oncolo_26_12_1052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T13:14:02Z","timestamp":1642598042000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/12\/1052\/6511619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":64,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,8,25]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13931","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,8,25]]}}}